Search for other papers by Ladan Mehran in
Google Scholar
PubMed
Search for other papers by Atieh Amouzegar in
Google Scholar
PubMed
Search for other papers by Hengameh Abdi in
Google Scholar
PubMed
Search for other papers by Negar Delbari in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Search for other papers by Elham Madreseh in
Google Scholar
PubMed
Search for other papers by Maryam Tohidi in
Google Scholar
PubMed
Search for other papers by Mohammad Ali Mansournia in
Google Scholar
PubMed
Search for other papers by Fereidoun Azizi in
Google Scholar
PubMed
individuals with and without MetS as well as evaluating the incidence of TD and trend of thyroid hormones according to the MetS group, during a 10 year follow-up in an iodine sufficient population. Materials and Methods Study Design TTS is a
Search for other papers by Cosimo Rodia in
Google Scholar
PubMed
Search for other papers by Francesca Menconi in
Google Scholar
PubMed
Search for other papers by Laura Mazoni in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Michele Marinò in
Google Scholar
PubMed
Graves’ hyperthyroidism since 1988, for which he had been treated with methimazole for 8 years, and then with radioactive iodine (in 1996), with consequent hypothyroidism, for which he was on L-thyroxine 150 µg/day. He reported the appearance of bilateral
Search for other papers by María de los Ángeles Garayalde Gamboa in
Google Scholar
PubMed
Search for other papers by Melina Saban in
Google Scholar
PubMed
Search for other papers by Marina Ines Curriá in
Google Scholar
PubMed
with 30 mCi of iodine 131 and oral LT4. During the following 3 years he had an excellent response receiving oral LT4 150 μg/day (2.14 μg/kg/day). In November 2017, he was hospitalized for intestinal subocclusion and secondary malabsorptive syndrome
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Kris Poppe in
Google Scholar
PubMed
Search for other papers by Simon H. Pearce in
Google Scholar
PubMed
hyperthyroidism is 1.2–1.6, 0.5–0.6 overt and 0.7–1.0% subclinical [ 1 , 5 ]. The most frequent causes are Graves’ disease (GD) and toxic nodular goiter. GD is the most prevalent cause of hyperthyroidism in iodine-replete geographical areas, with 20–30 annual
Search for other papers by Pedro Weslley Rosario in
Google Scholar
PubMed
Search for other papers by Gabriela Franco Mourão in
Google Scholar
PubMed
Search for other papers by Maria Regina Calsolari in
Google Scholar
PubMed
radioactive iodine (RAI), US should be obtained a few months later in all patients as part of the investigation that defines the response to therapy [ 1 - 3 ]. After this first assessment, the American Thyroid Association (ATA) [ 2 ] and the European Thyroid
Search for other papers by Alice Nervo in
Google Scholar
PubMed
Search for other papers by Alberto Ragni in
Google Scholar
PubMed
Search for other papers by Alessandro Piovesan in
Google Scholar
PubMed
Search for other papers by Valentina Marica in
Google Scholar
PubMed
Search for other papers by Enrica Migliore in
Google Scholar
PubMed
Search for other papers by Marco Gallo in
Google Scholar
PubMed
Search for other papers by Emanuela Arvat in
Google Scholar
PubMed
Introduction Treatment with lenvatinib (LEN), a multitarget tyrosine kinase inhibitor (TKI), has shown great efficacy in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC), both in clinical trials and in a real
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Hervé Monpeyssen in
Google Scholar
PubMed
Search for other papers by Andrea Frasoldati in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
vast majority of the thyroid nodule population but are not intended for pediatric cases. While TA is covered, in extenso, EA and radioactive iodine ablation procedures for thyroid nodules are only mentioned in passing. How the diagnosis of a benign
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Search for other papers by John B McIntyre in
Google Scholar
PubMed
Search for other papers by Adrian Box in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Search for other papers by Dean Ruether in
Google Scholar
PubMed
Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
were found in 12.6% of patients and RET gene fusions in 14.3% ( 13 ). The prevalence of fusions increases for metastatic/advanced patients’ WT of other aberrations. In radioactive iodine (RAI)-resistant metastatic thyroid cancers without BRAF
Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed
Search for other papers by Jennifer H Choe in
Google Scholar
PubMed
Search for other papers by Daniel W Bowles in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Search for other papers by Lori J Wirth in
Google Scholar
PubMed
Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed
Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed
Search for other papers by Francis P Worden in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) accounts for nearly 90% of all thyroid cancer cases ( 1 ). The standard initial treatment is surgery followed by radioactive iodine (RAI) or observation; however, approximately 5–15% of patients
Search for other papers by Yasuhiro Ito in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
-, and post-operative findings. They are useful in deciding therapeutic strategies, including the extent of surgery, adjuvant therapies such as radioactive iodine (RAI) administration, and postoperative follow-up imaging studies. Based on the 8th Edition